<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441788</url>
  </required_header>
  <id_info>
    <org_study_id>ION-827359-CS2</org_study_id>
    <secondary_id>2020-000210-15</secondary_id>
    <nct_id>NCT04441788</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Patients With Mild to Moderate COPD With Chronic Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of ION-827359 on forced expiratory volume&#xD;
      in 1 second (FEV1) in patients with mild to moderate COPD with CB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, double-blind, placebo-controlled, randomized, Phase 2a study of&#xD;
      ION-827359 in up to 180 participants. The participants will be randomized to receive oral&#xD;
      inhalation of either ION-827359 or placebo for up to 13 weeks. At the end of 13 weeks,&#xD;
      participants will enter a 10-week post-treatment evaluation period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Decision to Terminate Study&#xD;
  </why_stopped>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Actual">April 27, 2021</completion_date>
  <primary_completion_date type="Actual">April 27, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to the Primary Time Point in Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo</measure>
    <time_frame>From Baseline up to average of Weeks 13 and 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the EXACT Respiratory Symptoms (E-RS) Daily Symptom Diary to the Primary Time Point</measure>
    <time_frame>One week prior to first dose through one week after the last dose.</time_frame>
    <description>The EXACT (E-RS) scale is a participant-reported outcome (PRO) designed to measure the symptoms of participants with COPD. The E-RS utilizes 11 respiratory symptom items from the existing and validated 14-item EXACT, which measures symptoms of exacerbation. The E-RS total score quantifies respiratory symptom severity, and 3 domains assess breathlessness, cough and sputum, and chest symptoms. The E-RS will be collected on the daily e-diary, which will include all 14 items from the EXACT questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the COPD Assessment Test (CAT) to the Week 14 Time Point</measure>
    <time_frame>From Baseline up to Week 14</time_frame>
    <description>The CAT is an eight-item questionnaire that will be completed by the participant and is designed to quantify the impact of COPD symptoms on the health status of participants. The CAT provides a score of 0-40 to indicate the impact of the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) to the Week 14 Time Point</measure>
    <time_frame>From Baseline up to Week 14</time_frame>
    <description>The SGRQ is a participant completed, a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in participants with obstructive airway disease. Scores of the SGRQ-C range from 0 to 100, with higher scores indicating more limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Post-Bronchodilator FEV1</measure>
    <time_frame>From Baseline up to average of Weeks 13 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for ION-827359</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration for ION-827359</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC[0-t]: Area Under the Plasma Concentration-Time Curve from Time Zero to t for ION-827359</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Participants With at Least One Treatment-Emergent Adverse Event (TEAE), Graded by Severity</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Vital Signs Measurements</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Bronchitis</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>ION-827359</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose of ION-827359 will be administered by oral inhalation via nebulizer, once every week for up to 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single-dose of placebo will be administered by oral inhalation via nebulizer, once every week for up to 13 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ION-827359</intervention_name>
    <description>ION-827359 administered by oral inhalation</description>
    <arm_group_label>ION-827359</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered by oral inhalation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Must have given written informed consent (signed and dated) and any authorizations&#xD;
             required by local law and be able to comply with all study requirements&#xD;
&#xD;
          2. Males or females. Aged 40-70 inclusive at the time of informed consent&#xD;
&#xD;
          3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g.,&#xD;
             tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or&#xD;
             postmenopausal&#xD;
&#xD;
          4. BMI &lt; 35.0 kg/m2&#xD;
&#xD;
          5. Patients with a diagnosis of COPD as defined by the American Thoracic Society&#xD;
             (ATS)/European Respiratory Society (ERS)&#xD;
&#xD;
               1. Ability to perform acceptable and reproducible spirometry&#xD;
&#xD;
               2. Post-bronchodilator (4 puffs of albuterol) spirometry at Screening demonstrating&#xD;
                  the following:&#xD;
&#xD;
             i. FEV1/ forced vital capacity (FVC) ratio of &lt; 0.70 ii. FEV1 ≥ 50% and ≤ 90% of&#xD;
             predicted normal&#xD;
&#xD;
          6. Clinically stable COPD in the 4 weeks prior to Screening (Visit 1)&#xD;
&#xD;
          7. Current and former smokers with smoking history of ≥ 20 pack years&#xD;
&#xD;
          8. Meet SGRQ definition of CB&#xD;
&#xD;
          9. CAT score ≥ 10&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Clinically significant abnormalities in medical history (e.g., previous acute coronary&#xD;
             syndrome within 6 months of screening, congestive heart failure, major surgery within&#xD;
             3 months of Screening) or physical examination&#xD;
&#xD;
          2. Screening laboratory results as follows, or any other clinically significant&#xD;
             abnormalities in screening laboratory values that would render a subject unsuitable&#xD;
             for inclusion&#xD;
&#xD;
               1. Urine protein/creatinine (P/C) ratio ≥ 0.3 mg/mg. In the event of P/C ratio above&#xD;
                  this threshold eligibility may be confirmed by a quantitative total urine protein&#xD;
                  measurement of &lt; 300 mg/24 hr&#xD;
&#xD;
               2. Positive test (including trace) for blood on urinalysis. In the event of a&#xD;
                  positive test eligibility may be confirmed with urine microscopy showing ≤ 5 red&#xD;
                  blood cells per high power field&#xD;
&#xD;
               3. alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin,&#xD;
                  alkaline phosphatase (ALP), serum creatinine, blood urea nitrogen (BUN) &gt; 1.5 ×&#xD;
                  upper limit of normal (ULN)&#xD;
&#xD;
               4. Platelet count &lt; LLN&#xD;
&#xD;
               5. Serum potassium &gt; 5.2 mmol/L&#xD;
&#xD;
               6. Estimated GFR &lt; 60 mL/min (as determined by the Cockcroft-Gault Equation for&#xD;
                  creatinine clearance)&#xD;
&#xD;
               7. A positive PCR test for SARS-CoV-2 at any time prior to randomization&#xD;
&#xD;
          3. Any active infection requiring systemic antiviral or antimicrobial therapy that will&#xD;
             not be completed prior to first day Study Drug product is administered to the patient&#xD;
             (Study Day 1)&#xD;
&#xD;
          4. Unwillingness to comply with study procedures, including follow-up, as specified by&#xD;
             this protocol, or unwillingness to cooperate fully with the Investigator&#xD;
&#xD;
          5. Clinically important pulmonary disease other than COPD&#xD;
&#xD;
          6. Asthma as a primary or main diagnosis according to the Global Initiative for Asthma&#xD;
             (GINA) guidelines (GINA 2011) or other accepted guidelines. Patients with a past&#xD;
             medical history of asthma (e.g. childhood or adolescence) may be included&#xD;
&#xD;
          7. Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization for&#xD;
             a COPD exacerbation within 4 weeks prior to enrolment (Visit 1)&#xD;
&#xD;
          8. Acute upper or lower respiratory infection requiring antibiotics or antiviral&#xD;
             medication within 4 weeks prior to enrolment (Visit 1)&#xD;
&#xD;
          9. Long term oxygen therapy (LTOT)&#xD;
&#xD;
         10. Patients participating in, or scheduled for, an intensive (active) COPD rehabilitation&#xD;
             program (patients who are in the maintenance phase of a rehabilitation program are&#xD;
             eligible to take part)&#xD;
&#xD;
         11. Concomitant medication restrictions: Oral anticoagulants, oral steroids (e.g.&#xD;
             prednisone or Medrol), theophylline, chronic azithromycin, or roflumilast&#xD;
&#xD;
         12. Have any other conditions, which, in the opinion of the Investigator would make the&#xD;
             subject unsuitable for inclusion, or could interfere with the subject participating in&#xD;
             or completing the Study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MediTrial s.r.o.</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>37701</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plicni ambulance Kralupy</name>
      <address>
        <city>Kralupy Nad Vltavou</city>
        <zip>27801</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEFISPIRO s.r.o.</name>
      <address>
        <city>Lovosice</city>
        <zip>410 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plicni Ambulance Rokycany, s.r.o.</name>
      <address>
        <city>Rokycany</city>
        <zip>33701</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PNEUMOLOGIE VARNSDORF s.r.o.</name>
      <address>
        <city>Varnsdorf</city>
        <zip>40747</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologisches Studienzentrum Markgrafenstrasse</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MECS Research GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburger Institut far Therapieforschung GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLB Gesundheitsforschung Lubeck GmbH</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie Mainz Helix Medical Excellence Center Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZMS-Zentrum fur medizinische Studien GmbH</name>
      <address>
        <city>Warendorf</city>
        <zip>48231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csongrad Megyei Mellkasi Betegsegek Szakkorhaza</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Selye Janos Korhaz, Rendelointezet</name>
      <address>
        <city>Komarom</city>
        <zip>2900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Anne Street Medical Centre, Heart Lung Center</name>
      <address>
        <city>London</city>
        <zip>Nw1 8HU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>IONIS-ENaCRx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

